Enjoy complimentary customisation on priority with our Enterprise License!
The Antibacterial Drugs Market size is estimated to grow by USD 9.90 billion at a CAGR of 4.21% between 2022 and 2027. Market expansion is influenced by several factors, including the rising prevalence of bacterial infections, increasing awareness of diseases and their bacterial origins, and a globally aging population. Bacterial infections are becoming more common, necessitating effective treatments and driving the demand for related medications and therapies. Greater awareness of diseases caused by bacteria, their prevention, and treatment options is also contributing to market growth. Additionally, the global aging population is more susceptible to bacterial infections, further boosting the market for related treatments. These factors underscore the market's growth potential, indicating a need for continued development and innovation in bacterial infection treatments to meet the increasing demand.
The early diagnosis of diseases is essential to minimize the chances of happening severe damage to the body. The rising awareness of different infections, including TB, and their treatments are resulting in the growing use of antibacterial drugs for the treatment of these diseases in the primitive stages. Therefore, advanced formulations and innovative approaches enable the prevention of the spreading of disease and allow for early diagnosis. Novel mechanisms of action, combination therapies, and antibiotic development play a crucial role in this regard, highlighting the importance of innovation in healthcare. There is growing awareness among people due to several health awareness programs. For example, November 18 is celebrated as the European Antibiotic Awareness Day to increase awareness about antibiotic resistance and promote the judicious use of antibiotics. Hence, such awareness programs are positively impacting the market.
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
This report provides a detailed analysis of the market by and Route Of Administration (Intravenous, Oral, and Others ), Drug Class (B-lactam, Quinolones, Macrolids, Tetracyclins, and Others ), and Geography (Asia, North America, Europe, and Rest of World (ROW)).
The intravenous segment is estimated to witness significant growth during the forecast period. This segment plays a crucial role in the treatment of several infections, critical medical conditions, and situations where rapid and precise drug delivery is important. This route comprises injecting antibiotics directly into the bloodstream through a vein, enabling immediate distribution throughout the body.
Get a glance at the market contribution of various segments View a PDF Sample
The intravenous segment was the largest segment and was valued at USD 21.39 billion in 2017. There is increasing adoption of IV antibiotics across hospitals where the patient needs intensive care and frequent monitoring or cannot tolerate oral medications. Some of the main cases where antibiotics are administered intravenously include severe infection or antibiotics cannot be taken orally. The main types of intravenous administration types include injection and PICC lines. Some of the main infections that can be treated using this segment include pneumonia, severe urinary tract infections, certain intraabdominal infections, Gram-negative bacteremia, acute exacerbations of chronic lung disease, and skin and soft tissue infections. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.
B-Lactam antibiotics, also called B-lactams, comprise a key and widely utilized class of antibacterial drugs. These antibiotics are widely used to disrupt the synthesis of bacterial cell walls, a key component for bacterial survival and growth. Some of the main examples of B-lactam are penicillins and cephalosporins. As these antibiotics show different spectra of activity against various types of bacteria, it is widely used in treating a different range of infections. There is increasing adoption of these antibiotics as they are effective against Gram-positive bacteria. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.
Quinolone antibiotics also referred to as quinolones, comprise a key class of antibacterial drugs known for their effectiveness against a wide range of bacterial infections. Some of the main infections that can be treated using this segment include respiratory, urinary tract, skin, and gastrointestinal infections. Some of the main examples of quinolone include ciprofloxacin, levofloxacin, and moxifloxacin. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
Asia is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the antibacterial market during the forecast period. One of the main reasons which have significantly contributed to the growth of the global antibacterial drugs market is the growing demand for enhanced healthcare infrastructure in the region. Some of the Key leading markets which is contributing to the growth of this market in Asia include India and China.
Furthermore, the increase in the aging population is significantly fuelling the antibacterial market growth as the aging population has low immunity which makes them vulnerable to more diseases and infections. For example, as per the US Census Bureau's new report on aging, Asia had more than 4.5 billion people as of 2020, which is more than half of the world's population (including China and India, which have populations of over 1 billion each). Hence, such factors are expected to drive market growth in the region during the forecast period.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AbbVie Inc: The company offers anti-bacterial drugs such as AVYCAZ or ceftazidime and avibactam, TEFLARO or ceftaroline fosamil, DALVANCE or dalbavancin, and MONUROL.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is driven by organizations like the Pew Charitable Trust and initiatives like the Global Antibiotic Research and Development Partnership (GARDP), focusing on developing novel drug classes to combat Gram-negative ESKAPE bacteria. Progression through Phase 1, Phase 2, and Phase 3 clinical trials is crucial for promising molecules. Key players invest significantly in antibiotic development, bearing high expenses to address the challenge of drug-resistant bacteria. Efforts include screening over 50,000 compounds and accessing libraries like MTPC's to discover compounds with antibacterial activity. The market thrives on innovation, offering advanced formulations and combination therapies with novel mechanisms of action to tackle bacterial challenges and improve infectious disease management. Successful products undergo regulatory submissions and receive regulatory approval, leading to product expansion with novel formulations and combination therapies. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
One of the key factors driving the market growth is the rising aging population globally. There is an increasing prevalence of bacterial infections and diseases among the aging population. For example, as per the United Nations (UN) data, the number of persons aged 65 and above is expected to more than quadruple globally, from 761 million in 2021 to 1.6 billion in 2050.
Moreover, the elderly population has a compromised immune system due to age-related physiological changes, chronic conditions, and often complex healthcare needs which makes them more vulnerable to bacterial infections. Thus, such kinds of vulnerability can lead to serious complications and even death. Therefore, such factors are expected to drive market growth during the forecast period.
A key factor shaping the market growth is the application of nanotechnology in antibacterial drugs. There is an increase in infectious diseases which is the main cause of mortality in the healthcare industry. There is an increasing focus on the development of novel medications due to the emergence of microorganisms carrying multidrug resistance (MDR) rendering existing medications useless against them.
Moreover, several innovative methods are extensively utilized to inhibit antimicrobial medication resistance. Thus, there is increasing research and development on the application of nanotechnology in antibacterial drugs for effective cures against such bacterial infections. Hence, such factors are expected to drive market growth during the forecast period.
Regulatory hurdles related to developing antibacterial drugs are one of the key challenges hindering market growth. The main challenge faced by the global antibacterial market is the regulatory hurdles that come with certain complexities with regulatory approvals for the development, testing, and marketing of new antibiotics. Several stringent regulatory requirements are enforced to ensure patient safety and the efficacy of these life-saving medications.
Moreover, the development and launching of new antibiotics to market include rigorous preclinical testing, extensive clinical trials, and comprehensive data submissions to regulatory agencies. Therefore, the process itself is time-consuming and expensive. Hence, such factors are negatively impacting the market which in turn will hinder the market growth during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2022 for the following segments
The market is characterized by agreements such as MTPC's library access for initiatives like GARDP to meet market demand and address market concentration. Market offerings include pipeline products targeting bacteria like Staphylococci, Streptococci, Clostridium, and Listeria by inhibiting cell wall synthesis and targeting the peptidoglycan layer. While penicillin remains a significant segment, cephalosporins are also crucial, belonging to the beta-lactam group effective against Gram-negative bacteria like Pseudomonas aeruginosa and Klebsiella pneumonia.
Furthermore, the market sees a demand for bactericides fragilis and generics, with seasonal usage patterns and five generations of drugs, including cefixime for Enterobacteriaceae spp. Generic antibiotics and branded antibiotics segments coexist, with a focus on investigational pipelines and product offerings supported by robust distribution networks. Inhibitors of cell wall synthesis, including cephalosporin, penicillin, and carbapenems, are prominent, while novel drugs targeting RNA synthesis are also emerging. R&D initiatives drive product launches, with drugs like rifamycins and fidaxomycin targeting RNAP.
Market Scope |
|
Report Coverage |
Details |
Page number |
179 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.21% |
Market growth 2023-2027 |
USD 9.90 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
3.42 |
Regional analysis |
Asia, North America, Europe, and the Rest of World (ROW) |
Performing market contribution |
Asia at 42% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Basilea Pharmaceutica Ltd., Bayer AG, Binnopharm Group LLC, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Kyorin Pharmaceutical Co. Ltd., Lupin Ltd., Merck KGaA, Novartis AG, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Melinta Therapeutics LLC, and Shionogi and Co. Ltd. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the market forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.